Paclitaxel is part of the standard therapy for ovarian, fallopian tube, and primary peritoneal cancers. However, these cancers often continue growing despite this treatment. The purpose of this study is to assess the safety and effectiveness of adding the investigational drug MLN8237 (alisertib) to paclitaxel therapy in women with recurrent ovarian, fallopian tube, and primary peritoneal cancers. MLN8237 may increase the effectiveness of drugs like paclitaxel.
MLN8237 works by blocking aurora kinase, an enzyme that helps cancer cells divide and reproduce. MLN8237 is a pill that is taken orally (by mouth). Women will be randomly assigned to receive paclitaxel plus MLN8237 or paclitaxel alone.